Form D · Biotechnology
Secretome Therapeutics, Inc.
Dallas, TX · CIK 0001961833
Offering snapshot reported Feb 2, 2023 · SEC filing
- Reported sold
- $6.85M Offering amount: $10.9M
- Investors reported
- 48 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Nov 23, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 2, 2023 | Initial | $6,854,247 | No comparison | 48 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-472444
Source: Form D, filed Feb 2, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Vineet Jindal | Director, Executive |
| Sunjay Kaushal | Director |
| William Niland | Director |
| Henrik Rasmussen | Director |
| Angela Shen | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3060 Pegasus Park Dr Building 6
Dallas, TX, 75247
Dallas, TX, 75247